Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Teva Pharmaceutical ( (TEVA) ) has provided an update.
On June 5, 2025, Teva Pharmaceutical Industries Limited held its Annual Meeting where shareholders voted on several key matters. New board members were elected, including Chen Lichtenstein, Amir Elstein, Roberto A. Mignone, Dr. Perry D. Nisen, and Dr. Tal Zaks, with terms extending to 2027 and 2028. Additionally, shareholders approved various amendments related to executive compensation, including the compensation policy for executive officers and directors, the terms of office for the CEO, and compensation for non-employee directors and the non-executive Chairman of the Board. Kesselman & Kesselman was also appointed as the independent registered public accounting firm until the 2026 annual meeting. These decisions reflect a strategic alignment in Teva’s leadership and compensation structures, potentially impacting its governance and operational strategies.
The most recent analyst rating on (TEVA) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Teva Pharmaceutical stock, see the TEVA Stock Forecast page.
Spark’s Take on TEVA Stock
According to Spark, TipRanks’ AI Analyst, TEVA is a Neutral.
Teva’s overall score reflects its strong technical indicators and strategic financial management, which are offset by challenges in profitability and high leverage. The positive momentum in innovative brands and strategic focus on biosimilars provide growth potential, but valuation concerns persist due to negative profitability metrics.
To see Spark’s full report on TEVA stock, click here.
More about Teva Pharmaceutical
Teva Pharmaceutical Industries Limited is a leading global pharmaceutical company that specializes in generic and specialty medicines. The company focuses on developing, producing, and marketing a wide range of generic drugs and innovative specialty pharmaceuticals, catering to diverse healthcare needs worldwide.
Average Trading Volume: 12,435,832
Technical Sentiment Signal: Buy
Current Market Cap: $20.01B
Learn more about TEVA stock on TipRanks’ Stock Analysis page.